Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Debt (2016 - 2019)

Historic Total Debt for Fate Therapeutics (FATE) over the last 8 years, with Q3 2019 value amounting to $13.9 million.

  • Fate Therapeutics' Total Debt fell 627.65% to $13.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $13.9 million, marking a year-over-year decrease of 627.65%. This contributed to the annual value of $14.9 million for FY2018, which is 51.32% up from last year.
  • Per Fate Therapeutics' latest filing, its Total Debt stood at $13.9 million for Q3 2019, which was down 627.65% from $14.9 million recorded in Q2 2019.
  • Fate Therapeutics' 5-year Total Debt high stood at $19.7 million for Q2 2015, and its period low was $6.7 million during Q2 2017.
  • Moreover, its 5-year median value for Total Debt was $14.8 million (2018), whereas its average is $14.7 million.
  • In the last 5 years, Fate Therapeutics' Total Debt soared by 254008.04% in 2015 and then crashed by 5441.45% in 2017.
  • Over the past 5 years, Fate Therapeutics' Total Debt (Quarter) stood at $18.4 million in 2015, then tumbled by 41.84% to $10.7 million in 2016, then soared by 38.55% to $14.8 million in 2017, then grew by 0.51% to $14.9 million in 2018, then dropped by 6.4% to $13.9 million in 2019.
  • Its Total Debt stands at $13.9 million for Q3 2019, versus $14.9 million for Q2 2019 and $14.9 million for Q1 2019.